Page 92 - 《中国药房》2024年15期
P. 92

康莱特注射液辅助卡瑞利珠单抗联合化疗方案治疗晚期非小细

          胞肺癌的效果观察
                                       Δ


                *
          张晓晓 ,张祉薇,董晓倩,谢曼丽,邓皖利,张 铭(上海中医药大学附属普陀医院中医肿瘤科,上海 200062)

          中图分类号  R969.4;R979.1      文献标志码  A      文章编号  1001-0408(2024)15-1882-06
          DOI  10.6039/j.issn.1001-0408.2024.15.14

          摘   要  目的  观察康莱特注射液辅助卡瑞利珠单抗联合化疗方案治疗晚期非小细胞肺癌(NSCLC)的临床效果。方法  回顾性
          选择2018年1月1日至2022年12月1日在我院中医肿瘤科住院治疗的192例晚期NSCLC患者为研究对象,根据患者在卡瑞利珠
          单抗联合化疗(卡铂+培美曲塞)方案的基础上是否加用康莱特注射液分为观察组(加用,104例)和对照组(不加用,88例)。对比
          两组患者在治疗2、4、6个周期后的近期治疗效果,治疗前、治疗3个周期后、治疗结束时的外周血免疫功能指标和血清肿瘤标志物
          水平,以及远期治疗效果和住院治疗期间的不良反应发生情况。结果  在治疗 3 个周期后及治疗结束时,观察组患者外周血中
          CD4 T淋巴细胞比例和CD4 /CD8 均明显高于对照组(P<0.05),血清中癌胚抗原和细胞角质蛋白19片段抗原21-1水平均明显低
                                +
             +
                                    +
          于对照组(P<0.05);观察组患者的总生存期明显长于对照组(P<0.05),观察组与对照组患者的中位总生存期分别为(185.27±38.21)、
         (132.11±34.23) d;两组患者住院治疗期间出现的总体不良反应及≥3级不良反应比较,差异均无统计学意义(P>0.05)。结论  在卡瑞
          利珠单抗联合化疗方案的基础上加用康莱特注射液可进一步提高晚期NSCLC患者的免疫力,延长患者总生存期。
          关键词  康莱特注射液;卡瑞利珠单抗;联合化疗方案;非小细胞肺癌;临床疗效;总生存期

          Effect  observation  of  Kanglaite  injection  assisted  with  camrelizumab  combined  with  chemotherapy  in  the
          treatment of advanced NSCLC
          ZHANG Xiaoxiao,ZHANG Zhiwei,DONG Xiaoqian,XIE Manli,DENG Wanli,ZHANG Ming(Dept.  of  TCM
          Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China)

          ABSTRACT    OBJECTIVE  To  observe  the  clinical  efficacy  of  Kanglaite  injection  assisted  with  camrelizumab  combined  with
          chemotherapy  in  the  treatment  of  advanced  non-small  cell  lung  cancer (NSCLC).  METHODS  A  total  of  192  patients  with
          advanced NSCLC and hospitalized in the TCM oncology department of our hospital from January 1st, 2018 to December 1st, 2022
          were  retrospectively  selected  as  the  study  objects,  and  were  divided  into  observation  group (additional  use,  n=104)  and  control
          group (without  additional  use,  n=88)  according  to  whether  the  patients  additionally  received  Kanglaite  injection  based  on
          camrelizumab combined with chemotherapy (carboplatin+pemetrexed). The short-term therapeutic effects of 2,4 and 6 cycles were
          compared  between  the  two  groups.  The  levels  of  peripheral  blood  immune  function  indexes  and  serum  tumor  markers  were
          compared  before  treatment,  after  3  cycles  of  treatment  and  after  treatment.  The  long-term  therapeutic  effects  as  well  as  the
          occurrence  of  adverse  drug  reaction(ADR)  during  hospitalization  were  compared  between  the  two  groups.  RESULTS  After  3
          treatment  cycles  and  at  the  end  of  treatment,  the  CD4   T  lymphocyte  ratio  and  CD4 /CD8   in  the  observation  group  were  notably
                                                                               +
                                                    +
                                                                           +
          greater  than  the  control  group (P<0.05);  the  levels  of  serum  carcinoembryonic  antigen  and  cytokeratin  19  fragment  antigen  21-1
          were significantly lower than those in the control group (P<0.05). The overall survival of the observation group was significantly
          longer than that of the control group (P<0.05), and the median overall survival was (185.27±38.21) d and (132.11±34.23) d,
          respectively.  There  were  no  significant  differences  in  the  whole  ADR  and  grade  ≥3  ADR  between  the  two  groups  during
          hospitalization(P>0.05).  CONCLUSIONS  Based  on  camrelizumab  combined  with  chemotherapy,  the  addition  of  Kanglaite
          injection can enhance immunological response and prolong overall survival in advanced NSCLC patients.
          KEYWORDS     Kanglaite  injection;  camrelizumab;  combination  chemotherapy;  non-small  cell  lung  cancer;  clinical  efficacy;
          overall survival

              Δ 基金项目 上海市科技计划项目(No.20Y21900600);全国(上海
          市)名中医普陀传承工作室建设项目(No.ptzygzs2101);上海市普陀区                 肺癌是一种常见的呼吸道恶性肿瘤,在全球范围内
          中医临床重点专科建设项目(No.ptzyzk2101)
                                                              的恶性肿瘤中最常见且病死率最高,其中非小细胞肺癌
             *第一作者 副主任医师,硕士生导师,硕士。研究方向:中医药防
          治恶性肿瘤。E-mail:zxxgoodluck@163.com                   (non-small cell lung carcinoma,NSCLC)是肺癌的主要


          · 1882 ·    China Pharmacy  2024 Vol. 35  No. 15                            中国药房  2024年第35卷第15期
   87   88   89   90   91   92   93   94   95   96   97